Information about the Indian version of capmatinib, original research or imitation

Capmatinib is an oral MET tyrosine kinase inhibitor developed by Novartis. It is mainly used to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations. Since the drug received accelerated approval from the US FDA in 2020, it has become an important breakthrough in the field of precision therapy, especially providing new treatment hope for METex14 mutation patients who originally lacked targeted drug options. As the global market's attention to this drug continues to heat up, its supply situation in the Indian market has also become a focus of concern for many patients and medical professionals.

According to the current public information and market conditions, there is no original research version or legal generic version of capmatinib in India. In other words, Novartis has not officially launched the original drug of capmatinib in India, and major local generic drug companies in India, such as Natco, Cipla, Dr. Reddy’s, etc., have not yet obtained approval for the production of generic drugs of capmatinib. This is related to the fact that capmatinib is still in the global patent protection period and its clinical use is relatively new. As a result, generic drug registration channels for this drug have not yet been opened in many developing countries, including India.

Some drug suppliers in India may sell capmatinib products through some channels. These are usually original drugs obtained from other countries, such as the United States or European markets, and sold in India. Such drugs are often expensive, limited in quantity, and most are not available in conventional retail pharmacies. Instead, they rely on specialized transnational pharmaceutical supply chain services. Therefore, the fact that patients can "buy" capmatinib in India is mostly done through channel drugs or international drug purchases, which does not mean that the original or generic versions exist in India.

Reference materials:https://www.novartis.com/our-products/pipeline/capmatinib